Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.520
+0.050 (2.02%)
At close: Jun 26, 2026, 4:00 PM EDT
2.468
-0.052 (-2.07%)
After-hours: Jun 26, 2026, 5:15 PM EDT
Cellectar Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cellectar Biosciences stock have an average target of 10.33, with a low estimate of 10 and a high estimate of 11. The average target predicts an increase of 309.92% from the current stock price of 2.52.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2026.
Analyst Ratings
The average analyst rating for Cellectar Biosciences stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 2 | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Initiates $10 | Buy | Initiates | $10 | +296.83% | May 15, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $10 | Buy | Maintains | $10 | +296.83% | May 15, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $14 → $11 | Buy | Reiterates | $14 → $11 | +336.51% | May 5, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
6.77M
EPS This Year
-2.05
from -8.35
EPS Next Year
-1.60
from -2.05
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 20.3M | |
| Avg | n/a | 6.8M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 1,552.6% |
| Avg | - | 908.0% |
| Low | - | 178.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -2.05 | -1.60 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.